More insurance plans than ever are offering Taltz as the Preferred IL-17A antagonist across Commercial and Part D.Learn more
ADDITIONAL WEEK 12 RESULTS: In UNCOVER-1 (Taltz n=433; placebo n=431) and UNCOVER-3 (Taltz n=385; placebo n=193), Taltz patients achieved similar results: 89% and 87% of Taltz patients achieved PASI 75 vs 4% and 7% for placebo. Additionally, 35% and 38% achieved PASI 100 vs 0% and 0% for placebo and 82% and 81% of Taltz patients achieved sPGA 0,1 vs 3% and 7% for placebo.
In the maintenance period of UNCOVER-1 & UNCOVER -2, 75% of the patients receiving Taltz every 4 weeks who achieved sPGA 0,1 at week 12, maintained that response at week 60 (n=181*) compared with 7% of patients receiving placebo (n=203*) (NRI analysis).
Patients who achieved clear or almost clear skin (sPGA 0,1) after initial treatment with Taltz 80 mg every 2 weeks were re-randomized at week 12 to receive either Taltz 80 mg every 4 weeks (n=181*) or placebo (n=203*).
SELECT IMPORTANT SAFETY INFORMATION
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.